<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>American Diabetes Association Standards of Medical Care in Diabetes—2024</title>
</head>
<body>
    <header>
        <h1>American Diabetes Association Standards of Medical Care in Diabetes—2024</h1>
        <div class="authors">
            <p><strong>Authors:</strong> American Diabetes Association Professional Practice Committee</p>
            <p><strong>Publication:</strong> Diabetes Care, Volume 47, Supplement 1, January 2024</p>
            <p><strong>DOI:</strong> 10.2337/dc24-S001</p>
        </div>
    </header>

    <main>
        <section id="executive-summary">
            <h2>Executive Summary</h2>
            <p>The American Diabetes Association (ADA) Standards of Medical Care in Diabetes—2024 represents the most current evidence-based recommendations for the diagnosis and management of diabetes mellitus. These guidelines incorporate new evidence from major clinical trials and real-world studies published through 2023.</p>
            
            <div class="key-updates">
                <h3>Key Updates for 2024</h3>
                <ul>
                    <li>Expanded recommendations for continuous glucose monitoring (CGM) in type 2 diabetes</li>
                    <li>Updated cardiovascular risk assessment and management strategies</li>
                    <li>New guidance on diabetes technology integration</li>
                    <li>Enhanced focus on health equity and social determinants of health</li>
                </ul>
            </div>
        </section>

        <section id="diagnosis">
            <h2>2. Diagnosis and Classification of Diabetes</h2>
            
            <h3>2.1 Diagnostic Criteria</h3>
            <table border="1">
                <thead>
                    <tr>
                        <th>Test</th>
                        <th>Normal</th>
                        <th>Prediabetes</th>
                        <th>Diabetes</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Fasting Plasma Glucose</td>
                        <td>&lt;100 mg/dL</td>
                        <td>100-125 mg/dL</td>
                        <td>≥126 mg/dL</td>
                    </tr>
                    <tr>
                        <td>2-hour OGTT</td>
                        <td>&lt;140 mg/dL</td>
                        <td>140-199 mg/dL</td>
                        <td>≥200 mg/dL</td>
                    </tr>
                    <tr>
                        <td>HbA1c</td>
                        <td>&lt;5.7%</td>
                        <td>5.7-6.4%</td>
                        <td>≥6.5%</td>
                    </tr>
                    <tr>
                        <td>Random Plasma Glucose</td>
                        <td>N/A</td>
                        <td>N/A</td>
                        <td>≥200 mg/dL + symptoms</td>
                    </tr>
                </tbody>
            </table>

            <div class="recommendation-box">
                <h4>Recommendation 2.1</h4>
                <p><strong>Grade A:</strong> Testing for type 2 diabetes and prediabetes in asymptomatic adults should be considered in adults of any age who are overweight or obese (BMI ≥25 kg/m² or ≥23 kg/m² in Asian Americans) and who have one or more additional risk factors for diabetes.</p>
            </div>
        </section>

        <section id="glycemic-targets">
            <h2>6. Glycemic Targets</h2>
            
            <h3>6.1 HbA1c Goals</h3>
            <div class="recommendation-box">
                <h4>Recommendation 6.1</h4>
                <p><strong>Grade A:</strong> A reasonable HbA1c goal for many nonpregnant adults with diabetes is &lt;7% (53 mmol/mol).</p>
            </div>

            <div class="recommendation-box">
                <h4>Recommendation 6.2</h4>
                <p><strong>Grade C:</strong> More stringent HbA1c goals (such as &lt;6.5% [48 mmol/mol]) may be appropriate for selected individuals if this can be achieved without significant hypoglycemia or other adverse effects of treatment.</p>
            </div>

            <div class="recommendation-box">
                <h4>Recommendation 6.3</h4>
                <p><strong>Grade B:</strong> Less stringent HbA1c goals (such as &lt;8% [64 mmol/mol]) may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, extensive comorbid conditions, or long-standing diabetes in whom the goal is difficult to achieve despite diabetes self-management education, appropriate glucose monitoring, and effective doses of multiple glucose-lowering agents including insulin.</p>
            </div>

            <h3>6.2 Glucose Monitoring</h3>
            <div class="recommendation-box">
                <h4>Recommendation 6.4</h4>
                <p><strong>Grade A:</strong> Real-time continuous glucose monitoring (rtCGM) should be offered for diabetes management to adults with diabetes on intensive insulin therapy (multiple daily injections or insulin pump therapy).</p>
            </div>

            <div class="recommendation-box">
                <h4>Recommendation 6.5</h4>
                <p><strong>Grade B:</strong> Real-time continuous glucose monitoring may be beneficial for diabetes management in adults with type 2 diabetes not on intensive insulin therapy, particularly those on basal insulin therapy.</p>
            </div>
        </section>

        <section id="pharmacologic-therapy">
            <h2>9. Pharmacologic Approaches to Glycemic Treatment</h2>
            
            <h3>9.1 Type 2 Diabetes: Initial Therapy</h3>
            <div class="recommendation-box">
                <h4>Recommendation 9.1</h4>
                <p><strong>Grade A:</strong> Metformin is the preferred initial pharmacologic agent for type 2 diabetes unless contraindicated.</p>
            </div>

            <div class="recommendation-box">
                <h4>Recommendation 9.2</h4>
                <p><strong>Grade A:</strong> Early combination therapy should be considered in patients with newly diagnosed type 2 diabetes with HbA1c ≥9% (75 mmol/mol) to more rapidly achieve glycemic goals.</p>
            </div>

            <h3>9.2 Cardiovascular Disease Considerations</h3>
            <div class="recommendation-box">
                <h4>Recommendation 9.3</h4>
                <p><strong>Grade A:</strong> In patients with type 2 diabetes and established atherosclerotic cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP-1) receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen independent of HbA1c and in consideration of patient-specific factors.</p>
            </div>

            <div class="recommendation-box">
                <h4>Recommendation 9.4</h4>
                <p><strong>Grade A:</strong> In patients with type 2 diabetes and heart failure with reduced ejection fraction, an SGLT2 inhibitor with demonstrated benefit in heart failure outcomes is recommended as part of the glucose-lowering regimen independent of HbA1c and in consideration of patient-specific factors.</p>
            </div>

            <h3>9.3 Kidney Disease Considerations</h3>
            <div class="recommendation-box">
                <h4>Recommendation 9.5</h4>
                <p><strong>Grade A:</strong> In patients with type 2 diabetes and diabetic kidney disease, an SGLT2 inhibitor or nonsteroidal mineralocorticoid receptor antagonist with evidence of reducing kidney disease progression is recommended as part of the glucose-lowering regimen independent of HbA1c and in consideration of patient-specific factors.</p>
            </div>

            <h3>9.4 Weight Management Considerations</h3>
            <div class="recommendation-box">
                <h4>Recommendation 9.6</h4>
                <p><strong>Grade A:</strong> When weight loss is a major goal, a GLP-1 receptor agonist or dual GIP and GLP-1 receptor agonist with high efficacy for weight loss is recommended as part of the glucose-lowering regimen.</p>
            </div>
        </section>

        <section id="cardiovascular-disease">
            <h2>10. Cardiovascular Disease and Risk Management</h2>
            
            <h3>10.1 Blood Pressure</h3>
            <div class="recommendation-box">
                <h4>Recommendation 10.1</h4>
                <p><strong>Grade A:</strong> For most adults with diabetes and hypertension, a blood pressure target of &lt;130/80 mmHg is appropriate if it can be safely achieved.</p>
            </div>

            <div class="recommendation-box">
                <h4>Recommendation 10.2</h4>
                <p><strong>Grade A:</strong> For individuals with diabetes and hypertension at higher cardiovascular risk (existing atherosclerotic cardiovascular disease or 10-year atherosclerotic cardiovascular disease risk ≥15%), a blood pressure target of &lt;130/80 mmHg is recommended if it can be safely achieved.</p>
            </div>

            <h3>10.2 Lipid Management</h3>
            <div class="recommendation-box">
                <h4>Recommendation 10.3</h4>
                <p><strong>Grade A:</strong> Moderate-intensity statin therapy should be initiated or continued for adults with diabetes who are 40-75 years of age.</p>
            </div>

            <div class="recommendation-box">
                <h4>Recommendation 10.4</h4>
                <p><strong>Grade A:</strong> High-intensity statin therapy is reasonable for adults with diabetes who have multiple atherosclerotic cardiovascular disease risk factors and are 40-75 years of age.</p>
            </div>

            <h3>10.3 Antiplatelet Therapy</h3>
            <div class="recommendation-box">
                <h4>Recommendation 10.5</h4>
                <p><strong>Grade A:</strong> Use aspirin therapy (75-100 mg/day) as a secondary prevention strategy in those with diabetes and a history of atherosclerotic cardiovascular disease.</p>
            </div>
        </section>

        <section id="technology">
            <h2>7. Diabetes Technology</h2>
            
            <h3>7.1 Continuous Glucose Monitoring</h3>
            <div class="recommendation-box">
                <h4>Recommendation 7.1</h4>
                <p><strong>Grade A:</strong> Adults with diabetes on intensive insulin therapy should be offered continuous glucose monitoring to lower HbA1c levels and/or reduce hypoglycemia.</p>
            </div>

            <h3>7.2 Insulin Delivery Systems</h3>
            <div class="recommendation-box">
                <h4>Recommendation 7.2</h4>
                <p><strong>Grade B:</strong> Automated insulin delivery systems should be offered to youth and adults with type 1 diabetes who are capable of using the device safely (either by themselves or with a caregiver).</p>
            </div>

            <h3>7.3 Digital Health Tools</h3>
            <div class="recommendation-box">
                <h4>Recommendation 7.3</h4>
                <p><strong>Grade B:</strong> Digital health tools, including mobile applications and web-based platforms, may be considered as adjuncts to standard diabetes care to support self-management behaviors.</p>
            </div>
        </section>

        <section id="special-populations">
            <h2>14. Children and Adolescents</h2>
            
            <div class="recommendation-box">
                <h4>Recommendation 14.1</h4>
                <p><strong>Grade A:</strong> HbA1c should be measured quarterly in all children and adolescents with diabetes.</p>
            </div>

            <div class="recommendation-box">
                <h4>Recommendation 14.2</h4>
                <p><strong>Grade A:</strong> An HbA1c goal of &lt;7% (53 mmol/mol) is recommended for children and adolescents with type 1 diabetes.</p>
            </div>
        </section>

        <section id="quality-measures">
            <h2>Quality Measures</h2>
            
            <h3>Process Measures</h3>
            <ul>
                <li>HbA1c testing at least twice yearly</li>
                <li>Annual eye examination</li>
                <li>Annual foot examination</li>
                <li>Annual urine microalbumin testing</li>
                <li>Blood pressure measurement at every visit</li>
                <li>Lipid profile annually</li>
            </ul>

            <h3>Outcome Measures</h3>
            <ul>
                <li>HbA1c &lt;7% for most adults</li>
                <li>Blood pressure &lt;130/80 mmHg</li>
                <li>LDL cholesterol &lt;100 mg/dL (or &lt;70 mg/dL for high-risk patients)</li>
                <li>Absence of severe hypoglycemia</li>
                <li>Absence of diabetic ketoacidosis</li>
            </ul>
        </section>
    </main>

    <footer>
        <div class="citation">
            <h3>How to Cite</h3>
            <p>American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes—2024. <em>Diabetes Care</em> 2024;47(Suppl. 1):S1-S321. https://doi.org/10.2337/dc24-S001</p>
        </div>
        
        <div class="disclaimer">
            <h3>Disclaimer</h3>
            <p>The recommendations in this document are based on the evidence reviewed through 2023. The American Diabetes Association cannot guarantee the accuracy or completeness of the information presented and is not responsible for any errors or omissions or for the results obtained from the use of this information.</p>
        </div>
    </footer>
</body>
</html>